Stay in Touch
To keep in touch, please sign up to the Milltrust Ventures Newsletter for our latest news and insights.
Harry Paul has over 30 years’ executive experience in the Life Science sector.
Harry has worked in several international commercial and management roles at Roche and Boston Scientific where he developed close relationships with the clinical and scientific community. His interest in genetics led to his being part of Roche’s global team that launched the first therapeutic monoclonal antibody in oncology. At Boston Scientific he worked closely with physicians in a clinical and scientific setting to introduce new technologies in therapeutic areas such as neuro-interventionism and cardiology. Most recently he was CEO at Tharos, an animal health start-up company focused on developing animal feed solutions based on Gut Microbiome research.
He has his own consulting company that advises companies in the health sector on international business development, and has advised companies in areas such as regulatory strategy, clinical training for physicians, health economics and clinical study strategies for medical devices, as well as overall commercial strategy.
In addition, Harry has been an investor in agriculture in Latin America and has been involved in developing several investment projects in the region. He worked closely with Milltrust on their agricultural assignments in Latin America from 2013 to 2015. A member of Milltrust’s Investment Advisory Committee, he is involved in company assessments, deal sourcing, and strategic investors.
Passionate about building and nurturing successful and motivated teams, Harry has had the privilege of working with and developing several high-performing teams across the globe, particularly in the UK, US, Latin America and Asia.
A keen linguist, he speaks Spanish, Portuguese, French, as well as Italian, and he obtained his degree in Genetics and Microbiology from Leeds University.